Can a Real-World registry improve how treprostinil is used for PAH?
Disease control
Not yet recruiting
This registry follows adults newly diagnosed with pulmonary arterial hypertension (PAH) who are starting treatment with parenteral treprostinil, a medication given as a continuous infusion under the skin or into a vein. Researchers will collect data from routine care—including do…
Sponsor: AOP Orphan Pharmaceuticals AG • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC